RTX-240 Monotherapy and in Combination With Pembrolizumab

Clinical trial NCT04372706 · TERMINATED

Trial details

NCT number: NCT04372706
Sponsor: Rubius Therapeutics
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor, AML Adult

Start date: 2020-05-06
Primary completion: 2022-11-30
Enrollment: 69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.